Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|November 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trialNikki de Rouw, René J Boosman, Jacobus A Burgers, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Breast Cancer Research and Treatment|March 20, 2021
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE RegistryKhava I E Ibragimova, Sandra M E Geurts, Sander Croes, et al.
Clinical Pharmacology and Therapeutics|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal ImpairmentNikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 1, 2024
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLCNiels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, et al.
International Journal of Cancer|October 16, 2023
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancerArd van Veelen, G D Marijn Veerman, Marjon V Verschueren, et al.
Frontiers in Oncology|March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Pageof 5